Valneva (NASDAQ:VALN) Issues Earnings Results, Misses Expectations By $0.17 EPS

Valneva (NASDAQ:VALN) released its quarterly earnings data on Friday. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.17), Zacks reports. The company had revenue of $39.37 million during the quarter, compared to analysts’ expectations of $43.15 million. Valneva had a negative net margin of 88.87% and a negative return on equity of 107.63%.

Valneva Stock Performance

VALN stock traded up $1.48 during trading on Friday, reaching $7.13. The company had a trading volume of 2,800,516 shares, compared to its average volume of 68,534. The company has a market cap of $676.38 million, a price-to-earnings ratio of -3.81 and a beta of 1.77. Valneva has a twelve month low of $4.75 and a twelve month high of $12.25. The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.60 and a current ratio of 2.14. The firm has a 50-day simple moving average of $5.21 and a 200-day simple moving average of $6.92.

Trending Headlines about Valneva

Here are the key news stories impacting Valneva this week:

• Positive Sentiment: EMA review begins for Lyme vaccine: Pfizer and Valneva announced that the European Medicines Agency validated their marketing authorization application for the six-valent OspA-based Lyme disease vaccine candidate, PF-07307405. Validation means the application is complete and can enter formal regulatory assessment—an important milestone, though it does not guarantee approval. Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
• Positive Sentiment: Potentially large commercial opportunity: Coverage highlights the long-awaited development of a Lyme disease vaccine and suggests European regulatory decisions could come within roughly 12 months. A successful product could provide Valneva with a major new revenue stream through its partnership with Pfizer. EU to study potential vaccine for Lyme disease: companies
• Positive Sentiment: 2026 outlook reaffirmed: Valneva maintained its full-year financial guidance while outlining its strategic priorities and continued focus on its vaccine portfolio. This provides some reassurance despite quarterly results falling short of expectations. Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates
• Neutral Sentiment: New analyst coverage: TD Cowen initiated research coverage of Valneva. The available report does not specify a rating or price target, limiting its immediate investment significance. Valneva Research Coverage Started at TD Cowen
• Negative Sentiment: Quarterly results missed estimates: Valneva reported a loss of $0.40 per share versus the expected $0.23 loss, while revenue of $39.37 million was below the $43.15 million consensus. The company continues to report substantial net losses and negative return on equity, underscoring execution and funding risks. Valneva Earnings Results

Analyst Ratings Changes

VALN has been the subject of several recent research reports. The Goldman Sachs Group downgraded Valneva from a “neutral” rating to a “sell” rating and set a $4.90 price objective for the company. in a report on Wednesday, April 22nd. Wall Street Zen raised shares of Valneva from a “strong sell” rating to a “sell” rating in a research report on Monday, June 1st. Guggenheim set a $11.00 price target on shares of Valneva in a research report on Thursday, April 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Valneva in a research note on Thursday, June 18th. Finally, TD Cowen started coverage on shares of Valneva in a report on Tuesday. They set a “buy” rating and a $12.00 price objective on the stock. Four research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $11.98.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Marex Group plc acquired a new stake in shares of Valneva during the 2nd quarter valued at about $64,000. XTX Topco Ltd acquired a new position in Valneva in the 4th quarter worth about $94,000. Finally, JPMorgan Chase & Co. purchased a new position in Valneva during the third quarter worth approximately $124,000. Hedge funds and other institutional investors own 11.39% of the company’s stock.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.